Moleculin to Present at the 36th Annual ROTH Conference

Rhea-AI Summary

Moleculin Biotech, Inc. (MBRX) will have a fireside chat at the 36th Annual ROTH Conference on March 18th. Jonathan Foster, the CFO, will participate, showcasing the company's drug candidates for tumors and viruses.

Live webcast fireside chat on Monday, March 18^th at 9:00 AM PT

HOUSTON, March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin will participate in a fireside chat at the 36^th Annual ROTH Conference on March 18, 2024 at 9:00 AM PT.

In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website.

A live webcast of the fireside chat will be available on the Events page in the Investors section of the Company's website (moleculin.com). The webcast replay will be archived for 90 days following the event.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. 

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-36th-annual-roth-conference-302086104.html

SOURCE Moleculin Biotech, Inc.

FAQ

What is the date of the fireside chat at the 36th Annual ROTH Conference for Moleculin Biotech, Inc.?

The fireside chat is scheduled for March 18, 2024.

Who will be participating in the fireside chat for Moleculin Biotech, Inc. at the 36th Annual ROTH Conference?

Jonathan Foster, the Executive VP and CFO, will be participating.

What is the focus of Moleculin Biotech, Inc.'s drug candidates?

Moleculin Biotech's drug candidates target hard-to-treat tumors and viruses.

Will there be one-on-one in-person meetings with management at the conference?

Yes, management will be available for one-on-one in-person meetings with qualified members of the investor community.

What time will the fireside chat take place at the 36th Annual ROTH Conference?

The fireside chat is scheduled for 9:00 AM PT on March 18, 2024.